<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845257</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol DG3.0 - 25.06.2018</org_study_id>
    <nct_id>NCT03845257</nct_id>
  </id_info>
  <brief_title>Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma</brief_title>
  <official_title>Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific research focuses on &quot;eosinophilic inflammation&quot; as it seems to guide the&#xD;
      therapeutic regimen in patients with asthma and COPD. The primary objective of this&#xD;
      prospective trial is to evaluate which parameter(s) best reflects eosinophilic inflammation&#xD;
      by correlating tissue eosinophils (endobronchial biopsy, protected specimen brush sampling)&#xD;
      with FeNO, peripheral blood eosinophils, and eosinophils in the bronchoalveolar lavage of&#xD;
      patients with obstructive pulmonary disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective trial. Enrollment will continue until 150 patients with&#xD;
      chronic obstructive pulmonary disease and 50 patients with severe asthma have been entered&#xD;
      into this trial and have completed bronchoscopic evaluation. In this trial, the following&#xD;
      parameters are to be evaluated:&#xD;
&#xD;
        -  Blood eosinophils (absolute and relative)&#xD;
&#xD;
        -  FeNO&#xD;
&#xD;
        -  Eosinophils in bronchoalveolar lavage&#xD;
&#xD;
        -  Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">February 14, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of eosinophilic inflammation by correlating tissue eosinophilia with eosinophil count in blood/BAL and FeNO measurement.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of FeNO, blood eosinophils, bronchoalveolar lavage findings and bronchial epithelium histopathology in patients with chronic obstructive pulmonary disease and asthma</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obstructive Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with COPD</arm_group_label>
    <description>The following parameters are to be evaluated:&#xD;
Blood eosinophils&#xD;
FeNO&#xD;
Eosinophils in bronchoalveolar lavage&#xD;
Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with asthma</arm_group_label>
    <description>The following parameters are to be evaluated:&#xD;
Blood eosinophils&#xD;
FeNO&#xD;
Eosinophils in bronchoalveolar lavage&#xD;
Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling</intervention_name>
    <description>Blood sampling (eosinophil count; eosinophilia is defined as &gt;300/µl (or &gt;150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.</description>
    <arm_group_label>Patients with COPD</arm_group_label>
    <arm_group_label>Patients with asthma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of COPD or asthma (according to the guidelines)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of COPD or asthma (according to the guidelines)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Indication for bronchoscopy for medical reasons (not study-related)&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  paO2 &lt;60 mmHg on 4L 02 /min, paCO2 &gt; 55 mmHg on room air&#xD;
&#xD;
          -  FEV1 &lt;20%&#xD;
&#xD;
          -  Pulmonary infection or exacerbation within the last 4 weeks&#xD;
&#xD;
          -  Additional pulmonary diseases (pneumonia, lung cancer, tuberculosis, interstitial lung&#xD;
             disease)&#xD;
&#xD;
          -  Contraindication for BAL, PSB sampling or endobronchial biopsy&#xD;
&#xD;
          -  Current use of anticoagulants that can not be stopped for bronchoscopy&#xD;
&#xD;
          -  Heart failure with left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  Myocardial infarction in previous 6 months&#xD;
&#xD;
          -  Significant pulmonary hypertension (PAPS &gt;45 mmHg, right heart failure&#xD;
             [echocardiography] and/or PAPm &gt;35 mmHg [right heart catheter])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Gompelmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik University Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Gompelmann</last_name>
    <phone>004962213968087</phone>
    <email>daniela.gompelmann@directbox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Macquarie University Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alvin Ing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Clinical Infectious Diseases/Research Center Borstel</name>
      <address>
        <city>Borstel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Heyckendorf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik University Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Gompelmann</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Daniela Gompelmann</investigator_full_name>
    <investigator_title>Daniela Gompelmann, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

